J&J Should Pay Texas $579 Million for Risperdal, Jury Told
This article is for subscribers only.
Johnson & Johnson should reimburse at least $579 million to the Texas Medicaid system for fraudulently promoting its antipsychotic drug Risperdal for uses not approved by U.S. regulators, a state lawyer told jurors.
J&J, the world’s largest health care products company, is defending a lawsuit by Texas Attorney General Greg Abbott that claims the company and its Janssen unit overhyped and overcharged the state for the drug after its approval in 1993. J&J also promoted Risperdal for use by children before it got approval from the Food and Drug Administration, Texas claims.